Abrine Elicits Liver Carcinoma Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade by Modulating PD-L1 Signaling

Figure 4

Abrine epigenetically regulates PD-L1 expression via recruiting KAT5. (a–d) Levels of KAT5 (a, b) and PD-L1 (c, d) after transfection with siKAT5 and KAT5 overexpressing vectors (OE KAT5) were detected by qRT-PCR assay. (e) ChIP assay to check the interaction of KAT5 to PD-L1 promoter region. (f, g) Enrichment of H3K27Ac (f) and RNA pol II (g) on the PD-L1 promoter was assessed by ChIP assay under transfection with siKAT5 or NC. (h) Relative level of PD-L1 after transfection with KAT5 overexpressing vector (OE KAT5). Enrichment of H3K27Ac (i) and RNA pol II (j) on the PD-L1 promoter was assessed by ChIP assay under treatment with abrine and transfection with KAT5 overexpressing vector (OE KAT5). vs. control and abrine group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)